

March 30, 2020

President Donald J. Trump
White House
1600 Pennsylvania Ave NW
Washington D.C 20500

Stephen Hahn M.D.
Commissioner of Food and Drugs
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Chairman Daniel O'Day
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

Dear President Trump, Dr. Hahn, and Chairman O'Day,

We are healthcare providers from New York City, representing over 1,000 physicians and allied healthcare providers. We are writing to request respectfully that the FDA immediately grant Gilead Sciences, Inc. the approval to release Remdesivir in an Expanded Access program to ALL healthcare providers in this country infected by SARS-CoV-2 in the line of duties of fighting COVID-19.

Healthcare providers are at the forefront of our country's fight against COVID-19. Due to the persistent shortage of personal protection equipments (PPEs), many have been infected, and more and more are intubated and fighting for their lives. Sickening or death of healthcare providers due to COVID-19 not only impairs our frontline defenses against COVID-19 at this critical moment, but also adversely affects our ability to care for ALL illnesses now and in the future.

Remdesivir from Gilead has shown great potential in some clinical trials and case reports of treating COVID-19. Immediate order to approve Remdesivir in an Expanded Access program to all moderately or severely ill healthcare providers will send a powerful message of support to the entire healthcare community in the country. It will undoubtedly help save more lives, both the sickened healthcare providers and their patients. It will also become a potent and unique American weapon in our overall armamentarium in the global war to defeat the COVID-19 pandemic.

Sincerely,



George Liu, MD, Ph.D., FACP
President, CEO & CMO
Coalition of Asian-American IPA



Yick Moon Lee, MD, FAAP
President
Chinese American Medical Society